Galectin-3 activates spinal microglia to induce inflammatory nociception in wild type but not in mice modelling Alzheimer's disease

Nat Commun. 2023 Jun 22;14(1):3579. doi: 10.1038/s41467-023-39077-1.

Abstract

Musculoskeletal chronic pain is prevalent in individuals with Alzheimer's disease (AD); however, it remains largely untreated in these patients, raising the possibility that pain mechanisms are perturbed. Here, we utilise the TASTPM transgenic mouse model of AD with the K/BxN serum transfer model of inflammatory arthritis. We show that in male and female WT mice, inflammatory allodynia is associated with a distinct spinal cord microglial response characterised by TLR4-driven transcriptional profile and upregulation of P2Y12. Dorsal horn nociceptive afferent terminals release the TLR4 ligand galectin-3 (Gal-3), and intrathecal injection of a Gal-3 inhibitor attenuates allodynia. In contrast, TASTPM mice show reduced inflammatory allodynia, which is not affected by the Gal-3 inhibitor and correlates with the emergence of a P2Y12- TLR4- microglia subset in the dorsal horn. We suggest that sensory neuron-derived Gal-3 promotes allodynia through the TLR4-regulated release of pro-nociceptive mediators by microglia, a process that is defective in TASTPM due to the absence of TLR4 in a microglia subset.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease* / genetics
  • Animals
  • Chronic Pain* / genetics
  • Disease Models, Animal
  • Female
  • Galectin 3 / genetics
  • Hyperalgesia / genetics
  • Male
  • Mice
  • Mice, Transgenic
  • Microglia
  • Nociception
  • Spinal Cord
  • Spinal Cord Dorsal Horn
  • Toll-Like Receptor 4 / genetics

Substances

  • Galectin 3
  • Toll-Like Receptor 4